Quest Diagnostics (DGX) Stock: Why It Moved Today
Updated Oct 19, 2026, 12:05 PM ET · intraday price
- Trading at $234.80 as of 12:05 PM ET, -0.08% vs the prior close of $235.00.
- Volume 243.51K shares, 0.2x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
DGX is flat (-0.1%) to $234.80. Trading at $234.80 (intraday, 12:05 PM ET), -0.08% vs the prior close of $235.00. Day range $233.82–$235.99, opened at $234.40.
DGX daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — DGX is flat (-0.1%) to $234.80
- Trading at $234.80 (intraday, 12:05 PM ET), -0.08% vs the prior close of $235.00. Day range $233.82–$235.99, opened at $234.40.
- Volume was 243.51K shares, 0.2x its 50-day average of 1.00M — lighter than usual.
- Price is -1.1% vs its 50-day average ($237.36) and +12.3% vs its 200-day average ($209.16).
- 52-week range $171.18–$248.84; the current price sits at 82% of that range, 5.6% below the 52-week high.
Oct 16, 2026 — DGX dips 1.7% to $235.00
- Closed at $235.00, -1.74% vs the prior close of $239.15. Day range $233.56–$240.75, opened at $239.67.
- Volume was 799.64K shares, 0.8x its 50-day average of 996.93K.
- Price is -1.0% vs its 50-day average ($237.43) and +12.5% vs its 200-day average ($208.86).
- 52-week range $171.18–$248.84; today's close sits at 82% of that range, 5.6% below the 52-week high.
Oct 15, 2026 — DGX rises 2.5% to $239.15
- Closed at $239.15, +2.45% vs the prior close of $233.43. Day range $235.57–$239.17, opened at $235.85.
- Volume was 1.00M shares, 1.0x its 50-day average of 990.36K.
- Price is +0.7% vs its 50-day average ($237.50) and +14.7% vs its 200-day average ($208.56).
- 52-week range $171.18–$248.84; today's close sits at 88% of that range, 3.9% below the 52-week high.
Oct 14, 2026 — DGX rises 1.3% to $233.43
- Closed at $233.43, +1.29% vs the prior close of $230.46. Day range $231.32–$234.97, opened at $231.32.
- Volume was 1.20M shares, 1.2x its 50-day average of 984.41K.
- Price is -1.7% vs its 50-day average ($237.43) and +12.1% vs its 200-day average ($208.24).
- 52-week range $171.18–$248.84; today's close sits at 80% of that range, 6.2% below the 52-week high.
Oct 13, 2026 — DGX dips 0.9% to $230.46
- Closed at $230.46, -0.93% vs the prior close of $232.63. Day range $230.23–$234.33, opened at $233.13.
- Volume was 1.01M shares, 1.0x its 50-day average of 980.99K.
- Price is -2.9% vs its 50-day average ($237.44) and +10.8% vs its 200-day average ($207.95).
- 52-week range $171.18–$248.84; today's close sits at 76% of that range, 7.4% below the 52-week high.
Oct 12, 2026 — DGX rises 0.7% to $232.63, 3 up days in a row
- Closed at $232.63, +0.72% vs the prior close of $230.97. Day range $228.66–$234.64, opened at $228.66.
- Volume was 865.20K shares, 0.9x its 50-day average of 981.13K.
- Price is -2.0% vs its 50-day average ($237.47) and +12.0% vs its 200-day average ($207.68).
- 52-week range $171.18–$248.84; today's close sits at 79% of that range, 6.5% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — DGX ends flat (+0.1%) to $230.97
- Closed at $230.97, +0.07% vs the prior close of $230.81. Day range $227.86–$232.18, opened at $227.86.
- Volume was 775.40K shares, 0.8x its 50-day average of 984.58K.
- Price is -2.7% vs its 50-day average ($237.47) and +11.4% vs its 200-day average ($207.39).
- 52-week range $171.18–$248.84; today's close sits at 77% of that range, 7.2% below the 52-week high.
Oct 8, 2026 — DGX rises 1.7% to $230.81
- Closed at $230.81, +1.65% vs the prior close of $227.06. Day range $226.36–$231.08, opened at $228.16.
- Volume was 941.90K shares, 1.0x its 50-day average of 985.03K.
- Price is -2.8% vs its 50-day average ($237.54) and +11.4% vs its 200-day average ($207.12).
- 52-week range $171.18–$248.84; today's close sits at 77% of that range, 7.2% below the 52-week high.
Oct 7, 2026 — DGX dips 0.6% to $227.06, a 1-month low, 3 down days in a row
- Closed at $227.06, -0.58% vs the prior close of $228.39. Day range $226.81–$229.80, opened at $228.51.
- Volume was 927.40K shares, 0.9x its 50-day average of 998.72K.
- Price is -4.4% vs its 50-day average ($237.63) and +9.8% vs its 200-day average ($206.85).
- 52-week range $171.18–$248.84; today's close sits at 72% of that range, 8.8% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — DGX dips 1.6% to $228.39, a 1-month low on 1.8x normal volume
- Closed at $228.39, -1.65% vs the prior close of $232.22. Day range $225.78–$232.09, opened at $229.92.
- Volume was 1.78M shares, 1.8x its 50-day average of 985.91K — unusually heavy trading.
- Price is -4.0% vs its 50-day average ($237.81) and +10.6% vs its 200-day average ($206.59).
- 52-week range $171.18–$248.84; today's close sits at 74% of that range, 8.2% below the 52-week high.
- SEC filings that day: 8-K.
Oct 5, 2026 — DGX dips 0.5% to $232.22
- Closed at $232.22, -0.48% vs the prior close of $233.33. Day range $229.96–$233.65, opened at $232.93.
- Volume was 1.01M shares, 1.0x its 50-day average of 996.47K.
- Price is -2.4% vs its 50-day average ($237.88) and +12.5% vs its 200-day average ($206.35).
- 52-week range $171.18–$248.84; today's close sits at 79% of that range, 6.7% below the 52-week high.
Oct 2, 2026 — DGX rises 1.0% to $233.33
- Closed at $233.33, +0.97% vs the prior close of $231.09. Day range $228.83–$233.48, opened at $230.58.
- Volume was 1.10M shares, 1.0x its 50-day average of 1.05M.
- Price is -1.9% vs its 50-day average ($237.79) and +13.2% vs its 200-day average ($206.08).
- 52-week range $171.18–$248.84; today's close sits at 80% of that range, 6.2% below the 52-week high.
DGX bull case vs bear case (from the data)
- Price is +12.3% vs its 200-day average — above the long-term trend line.
- Annual revenue grew 11.8% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: profit of $992.00M.
- Price is -1.1% vs its 50-day average — short-term trend is down.
- Insider selling outweighs buying: 25 sales vs 0 open-market buys among the 25 most recent reported insider trades (Form 4, last 12 months).
DGX latest news & SEC filings
Every SEC filing by or about DGX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Davis J. E. sold 10,000 shares at $242.72 (≈$2.43M) on Sep 1, 2026
- Davis J. E. sold 10,000 shares at $242.72 (≈$2.43M) on Sep 1, 2026
- Davis J. E. sold 10,000 shares at $242.72 (≈$2.43M) on Sep 1, 2026
- Davis J. E. sold 10,000 shares at $242.72 (≈$2.43M) on Sep 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 31, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Prevoznik Michael E sold 430 shares at $244.51 (≈$105.14K) on Aug 28, 2026
- Prevoznik Michael E sold 6,237 shares at $243.63 (≈$1.52M) on Aug 28, 2026
- Prevoznik Michael E sold 16,010 shares at $242.88 (≈$3.89M) on Aug 28, 2026
- Prevoznik Michael E sold 430 shares at $244.51 (≈$105.14K) on Aug 28, 2026
- Prevoznik Michael E sold 6,237 shares at $243.63 (≈$1.52M) on Aug 28, 2026
- Prevoznik Michael E sold 16,010 shares at $242.88 (≈$3.89M) on Aug 28, 2026
- …plus 6 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 28, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Delaney Mark E sold 1,600 shares at $235.18 (≈$376.29K) on Jul 28, 2026
- Delaney Mark E sold 1,600 shares at $235.18 (≈$376.29K) on Jul 28, 2026
- Delaney Mark E sold 1,600 shares at $235.18 (≈$376.29K) on Jul 28, 2026
- Delaney Mark E sold 1,600 shares at $235.18 (≈$376.29K) on Jul 28, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 23, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $3.04B (prior year $2.76B) (+10.2% vs Jun 30, 2025)
- Net income: $320.00M (prior year $282.00M) (+13.5% vs Jun 30, 2025)
- Diluted EPS: $2.84 (prior year $2.47) (+15.0% vs Jun 30, 2025)
Jul 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade DGX
- Last results release: Jul 23, 2026 (8-K Item 2.02). Previous ones: Apr 21, 2026, Feb 10, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 22, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.17% (largest 4.1%).
- Liquidity: about 1.09M shares (≈$256.37M) trade per day on average.
- 52-week position: $234.80 vs a range of $171.18–$248.84 (82% of the range).
- Dividends: last ex-dividend date Oct 6, 2026 ($0.86/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: J. E. Davis sold 10,000 shares on Sep 1, 2026.
- Latest filings: 8-K Oct 6, 2026; 10-Q Jul 23, 2026; 8-K Jul 23, 2026.
- Share count: 110.37M shares outstanding (Jul 15, 2026), -1.3% vs a year earlier.
- Listing: NYSE · industry: Services-Medical Laboratories.
DGX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 234.40 | 235.99 | 233.82 | 234.80 | 243.51K |
| Oct 16, 2026 | 239.67 | 240.75 | 233.56 | 235.00 | 799.60K |
| Oct 15, 2026 | 235.85 | 239.17 | 235.57 | 239.15 | 1.00M |
| Oct 14, 2026 | 231.32 | 234.97 | 231.32 | 233.43 | 1.20M |
| Oct 13, 2026 | 233.13 | 234.33 | 230.23 | 230.46 | 1.01M |
| Oct 12, 2026 | 228.66 | 234.64 | 228.66 | 232.63 | 865.20K |
| Oct 9, 2026 | 227.86 | 232.18 | 227.86 | 230.97 | 775.40K |
| Oct 8, 2026 | 228.16 | 231.08 | 226.36 | 230.81 | 941.90K |
| Oct 7, 2026 | 228.51 | 229.80 | 226.81 | 227.06 | 927.40K |
| Oct 6, 2026 | 229.92 | 232.09 | 225.78 | 228.39 | 1.78M |
| Oct 5, 2026 | 232.93 | 233.65 | 229.96 | 232.22 | 1.01M |
| Oct 2, 2026 | 230.58 | 233.48 | 228.83 | 233.33 | 1.10M |
| Oct 1, 2026 | 232.74 | 233.33 | 230.47 | 231.09 | 992.20K |
| Sep 30, 2026 | 233.33 | 236.97 | 230.84 | 233.07 | 1.09M |
| Sep 29, 2026 | 235.46 | 237.62 | 230.98 | 231.97 | 1.54M |
| Sep 28, 2026 | 234.27 | 238.10 | 233.81 | 237.62 | 1.03M |
| Sep 25, 2026 | 236.37 | 238.25 | 235.48 | 236.32 | 741.70K |
| Sep 24, 2026 | 234.08 | 237.29 | 233.55 | 236.59 | 926.90K |
| Sep 23, 2026 | 235.12 | 238.62 | 231.92 | 233.00 | 1.13M |
| Sep 22, 2026 | 228.59 | 237.29 | 227.24 | 234.76 | 2.72M |
About Quest Diagnostics
Quest Diagnostics (DGX) is listed on the NYSE and classified by the SEC under “Services-Medical Laboratories”. Its business address is in SECAUCUS, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1022079.
DGX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Robert B Carter | Director | Jul 27, 2026 |
| J. E. Davis | CEO and President | Sep 3, 2026 |
| Luis Diaz | Director | May 21, 2026 |
| Tracey Doi | Director | May 21, 2026 |
| Vicky B Gregg | Director | Jul 27, 2026 |
| Wright Iii Lassiter | Director | Jul 27, 2026 |
| Timothy L Main | Director | Jul 27, 2026 |
| Denise M Morrison | Director | May 21, 2026 |
| Gary M Pfeiffer | Director | May 21, 2026 |
| Timothy M Ring | Director | May 21, 2026 |
| Timothy C Wentworth | Director | Jul 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Mark E Delaney | SVP & Chief Commercial Officer | Jul 29, 2026 |
| J. E. Davis | CEO and President | Sep 3, 2026 |
| Michael J Deppe | SVP, Corp. Controller & CAO | Mar 6, 2026 |
| Catherine T. Doherty | EVP, Regional Businesses | Mar 6, 2026 |
| Karthik Kuppusamy | SVP, Clinical Solutions | Jul 27, 2026 |
| Michael E Prevoznik | SVP & General Counsel | Aug 31, 2026 |
| Patrick Plewman | SVP for Diagnostic Services | Jul 27, 2026 |
| Sam Samad | Executive Vice President & CFO | Jul 27, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 1, 2026 | J. E. Davis | Sale | 10,000 | $242.72 |
| Sep 1, 2026 | J. E. Davis | Sale | 10,000 | $242.72 |
| Sep 1, 2026 | J. E. Davis | Sale | 10,000 | $242.72 |
| Sep 1, 2026 | J. E. Davis | Sale | 10,000 | $242.72 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 430 | $244.51 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 6,237 | $243.63 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 16,010 | $242.88 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 430 | $244.51 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 6,237 | $243.63 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 16,010 | $242.88 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 430 | $244.51 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 6,237 | $243.63 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 16,010 | $242.88 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 430 | $244.51 |
| Aug 28, 2026 | Michael E Prevoznik | Sale | 6,237 | $243.63 |
DGX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $11.04B | $992.00M | 8.75 | $1.89B |
| Dec 31, 2024 | $9.87B | $871.00M | 7.69 | $1.33B |
| Dec 31, 2023 | $9.25B | $854.00M | 7.49 | $1.27B |
| Dec 31, 2022 | $9.88B | $946.00M | 7.97 | $1.72B |
| Dec 31, 2021 | $10.79B | $2.00B | 15.55 | $2.23B |
Latest balance sheet: total assets $16.94B, total liabilities $—, cash $626.00M (as of Jun 30, 2026).
DGX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 23, 2026 | 8-K Item 2.02 (results) | $227.90 |
| Apr 21, 2026 | 8-K Item 2.02 (results) | $205.04 |
| Feb 10, 2026 | 8-K Item 2.02 (results) | $205.35 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $175.94 |
| Oct 21, 2025 | 8-K Item 2.02 (results) | $184.64 |
| Jul 22, 2025 | 8-K Item 2.02 (results) | $178.24 |
| Apr 22, 2025 | 8-K Item 2.02 (results) | $172.84 |
| Jan 30, 2025 | 8-K Item 2.02 (results) | $164.17 |
| Oct 22, 2024 | 8-K Item 2.02 (results) | $157.47 |
| Jul 23, 2024 | 8-K Item 2.02 (results) | — |
| Apr 23, 2024 | 8-K Item 2.02 (results) | — |
| Feb 1, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Services-Medical Laboratories
Natera (NTRA)Guardant Health (GH)Labcorp (LH)Grail (GRAL)Caris Life Sciences (CAI)Celcuity (CELC)CareDx (CDNA)BillionToOne (BLLN)Veracyte (VCYT)RadNet (RDNT)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on DGX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 19, 2026, 12:05 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.